Perrigo CEO Takes Faith In Rx Generics Business To Exit Door With Him
Executive Summary
Private label OTC business is likely to be strengthened as Perrigo’s core, as CEO Hendrickson announces retirement shortly after hedge fund investor Starboard Value, pushing to divest the Rx business, built a five-seat block on Perrigo's board.
You may also be interested in...
Perrigo Closes Q1 Earnings Saga Trying To Keep Grip On Rx Business
The OTC drug private label giant's share price increased as much as 5% in heavy trading May 31 after the release a day earlier of its complete 2017 first-quarter earnings statement and its announcement of $1.4bn in tender offers for credit notes due starting in 2021.
Perrigo Trims Workforce, Ships Tysabri License, Stays European Course
The firm is reducing its non-production workforce by 750, a decision made after three representatives of disgruntled investor Starboard Value joined its board. Perrigo charts a course of recovery for its struggling international consumer health business, but some analysts are convinced it took a wrong turn with its 2015 investment in European OTC drug and nutritional product businesses and brands.
Perrigo OTC Brand Journey Detours Into Management, Operating Problems
The firm's report of problems in its European branded product business during its earnings briefing prompted a sharp dip in its share price, closing down more than 10% at $130.40, and left analysts looking for its private label OTC business to continue as its growth driver.